Zyronax Methocarbamol Tablet

Zyronax

Methocarbamol USP 500mg Tablets

 

COMPOSITION

Each uncoated Tablet contains:

Methocarbamol USP 500 mg.

Excipients q.s.

 

PHARMACOLOGICAL CLASSIFICATION

Other Analgesics.

 

PHARMACOLOGICAL ACTION

Methocarbamaol has analgesic, anti-inflammatory, anti-pyretic and muscle-relaxant properties. Methocarbamol is a muscle relaxant whose mechanism of action in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fibre.

 

INDICATIONS

Methocarbamaol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

 

CONTRAINDICATIONS

Methocarbamol is contra-indicated in patients with CNS depressed, coma or pre-coma states, brain damage, myasthenia gravis or in patients with a history of epilepsy.

 

PREGNANCY

Safe use of METHOCARBAMAOL has not been established. Not to be taken during the first or last three months of pregnancy unless prescribed by a doctor.

Nursing mothers

Nursing should not be undertaken while a patient is being treated with this medicine.

 

WARNINGS

Do not use continuously for more than 10 days without consulting your doctor.

Consult a doctor if pain or fever persists or gets worse, if new symptoms occur or if redness and swelling is present, as these could be signs of a serious condition.

To be used with caution in patients with liver or renal disease and only under the supervision of a doctor.

Toxic effects are more likely in the elderly and those suffering from dehydration, due to reduced renal function.

Do not take this product if you are presently taking a prescription medicine for anticoagulation, diabetes, gout or arthritis unless directed by a doctor.

 

DOSAGE AND DIRECTIONS FOR USE

Adults and children of 12 years of age

Two tablets four times daily.

These dosage recommendations provide respectively 3.2 g and 4.8 g of methocarbamol per day.

Elderly

Half the maximum recommended adult dose or less, may be sufficient to produce a therapeutic response in the elderly.

Children

Not Recommended.

Gastric irritation may be reduced by taking doses after food.

 

SIDE-EFFECTS AND SPECIAL PRECAUTIONS

Side-effects

Side-effects reported with methocarbamol include lightheadedness, anorexia, dizziness, drowsiness, nausea and vomiting, allergic manifestations, such as urticaria, pruritis, rash, angioneurotic oedema, conjunctivitis with nasal congestion, blurred vision, headache and fever.

Methocarbamol may rarely give rise to leucopenia, restlessness, anxiety, vertigo, tremor, confusion, and convulsions.

Special precautions

Gastrointestinal discomfort may be minimised by taking METHOCARBAMAOL with food.

METHOCARBAMAOL should be used with caution in patients with compromised cardiac function or hypertension, renal and hepatic insufficiency. Toxic effects are more likely in the elderly and those suffering from dehydration, due to reduced renal function.

Paediatric use

Safety and effectiveness in children 12 years of age and below has not been established.

Interactions

The effects of methocarbamol may be potentiated by concomitant administration of other CNS depressants and stimulants including alcohol, barbiturates, anaesthetics and appetite suppressants. The effects of anorectics, anticholinergics (e.g. atropine), and some psychotropic agents may be potentiated by methocarbamol.

 

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT

Symptoms of overdosage

Methocarbamol: Extreme drowsiness.

Treatment of overdosage

Gastric lavage is recommended with appropriate symptomatic and supportive therapy for at least 24 hours as methocarbamol is excreted at that time.

 

PRESENTATION

ZYRONAX 1 x 10: Each strip contain 10 tablets.

 

STORAGE INSTRUCTIONS

Store in cool, dry and dark place.

 

KEEP OUT OF REACH OF CHILDREN.

 

NAFDAC Reg. No.: B4-1959
Mfg. Lic. No.: G/25/1905

 

Manufactured by

Zota Health Care Ltd.,

Plot No. 169, Surat Special Economic Zone,

Sachin, Surat-394 230. (Gujarat) INDIA.

 

Marketed by

FAMZY NIGERIA LIMITED

Plot 1c, Chime Lane, G.R.A. Enugu,

Nigeria.

www.famzy.com

Advertisements